

## Special Issue

# New Advances in Mesenchymal Stromal Cells as Therapeutic Tools

### Message from the Guest Editor

In recent decades, studies on the biology and therapeutic potential of mesenchymal stromal cells (MSC) have attracted significant interest and have proven to be a promising tool for regenerative medicine.

The purpose of this Special Issue is to bring together contributions from specialists in Cellular Biology, Stem Cells, Immunology and Bioengineering on the latest advances in understanding of the mechanisms of action underlying the therapeutic effect of MSCs, in clinical applications of MSCs for treatment of inflammatory and degenerative diseases/conditions, in developing bioengineering/priming solutions to enhance MSC effectiveness, and in establishing bioprocessing platforms for large scale MSC production for clinical applications.

---

### Guest Editor

Dr. Kelen Cristina Ribeiro Malmegrim

School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, São Paulo, Brazil

---

### Deadline for manuscript submissions

closed (31 May 2024)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/126839](https://mdpi.com/si/126839)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)